Biohaven Pharmaceutical Stock Price - BHVN

44.16
0.00 (0.00%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
$52.04
Small Cap Basic
Monthly Subscription
for only
$33.03
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
$67.09
VAT not included
Company Name Stock Ticker Symbol Market Type
Biohaven Pharmaceutical Holding Company Ltd BHVN NYSE Common Stock
  Price Change Change Percent Stock Price Low Price High Price Open Price Close Price Last Traded
3.34 8.18% 44.16 40.80 44.20 41.50 40.82 20:00:00
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
14,709 1,874,340 $ 42.31 $ 79,312,341 1,147,405 36.69 - 67.86
Last Trade Time Type Quantity Stock Price Currency
18:30:00 152,256 $ 44.16 USD

Biohaven Pharmaceutical Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 2.52B 57.07M $ -240.92M -6.19 - 51.26M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
7.97M $ - 0.00% - -

more financials information »

Biohaven Pharmaceutical News

Loading Messages....

Latest BHVN Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical BHVN Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week45.8045.9140.7843.84832,495-1.64-3.58%
1 Month48.7054.8838.5047.451,102,828-4.54-9.32%
3 Months55.2062.0038.5051.07946,120-11.04-20.0%
6 Months37.5862.0037.0849.05776,6716.5817.51%
1 Year44.8667.8636.6948.78804,670-0.70-1.56%
3 Years20.0067.8616.500140.81516,83924.16120.8%
5 Years20.0067.8616.500140.81516,83924.16120.8%

Biohaven Pharmaceutical Description

Biohaven Pharmaceutical Holding Co Ltd is a clinical-stage biopharmaceutical company. It has a portfolio of late-stage product candidates targeting neurological diseases, including rare disorders. Its product candidates are based on multiple mechanisms-calcitonin gene-related peptide receptor antagonists, glutamate modulators and myeloperoxidase inhibitor. The company's pipeline products include BHV3000-301, BHV3000-302, BHV3000-303 and others.


Your Recent History
NYSE
BHVN
Biohaven P..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.